Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7009789 + atezolizumab dose-escalation study in advanced/metastatic solid tumors
NL-OMON44807Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Dec 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of selicrelumab and atezolizumab in Nonhematologic neoplasms (3 arms), sponsored by Roche. Started Dec 2014; status: active, not recruiting.
02
Drugs
selicrelumabatezolizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON44807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44807.